Ludwig-Maximilians-Univeritiät Munich
Department of Psychiatry and Psychotherapy
Peter Falkai has been working in the field of psychiatry for 30 years. His main research interest is focused on the neurobiology of psychotic disorders, namely schizophrenia. He holds the position of Chair of the Department of Psychiatry and Psychotherapy of the University of Munich. Prof. Falkai has been leading multidisciplinary teams of researchers, allowing the use of techniques ranging from functional imaging to gene expression in human post-mortem-tissue. His clinical and research expertise focuses continuously on the neurobiological origins and pathomorphological aspects as well as on causal treatment options of psychotic disorders.

Moderator Of 14 Sessions

Session Type
Clinical/Therapeutic
Date
Sun, 05.06.2022
Session Time
15:00 - 16:30
Room
Hall A
Session Icon
Fully Live
Session Type
EPA Forum
Date
Sat, 04.06.2022
Session Time
09:00 - 12:00
Room
Hall A
Session Icon
Fully Live

Saturday, 4 June: Congress Opening

Session Type
EPA TV
Date
Sat, 04.06.2022
Session Time
17:00 - 17:30
Room
EPA TV
Session Icon
Fully Live, Live TV

Sunday, 5 June: Daily Overview

Session Type
EPA TV
Date
Sun, 05.06.2022
Session Time
09:30 - 10:00
Room
EPA TV
Session Icon
Fully Live, Live TV

Sunday, 5 June: Midday Interviews

Session Type
EPA TV
Date
Sun, 05.06.2022
Session Time
11:30 - 12:00
Room
EPA TV
Session Icon
Fully Live, Live TV
Session Type
Mental Health Policy
Date
Mon, 06.06.2022
Session Time
08:00 - 09:30
Room
Hall B
Session Description
The issues of involuntary treatment in psychiatry have been the subject of a new round of legal, ethical and clinical discussions both within the professional community and in society since the publication of the United Nations Convention on the Rights of Persons with Disabilities authoritative interpretations. The symposium will present general data on the involuntary admission procedures of patients with mental disorders in 40 European countries, but also focus on what changes early career psychiatrists can make in their clinical practice to implement alternatives to coercion in mental health care, as well as efficacy of interventions to reduce coercive treatment in mental health services. The symposium will also focus on the less studied topic of involuntary hospitalization in children or adolescents, and will attempt to answer the question of whether the COVID-19 pandemic has brought about changes in the use of involuntary treatment in psychiatry. As an outcome of the symposium, attendees will become more familiar with both the general aspects of current involuntary psychiatric practice in Europe and those practical changes that clinicians can implement in their practice to continue the efforts to reduce coercion in psychiatry.
Session Icon
ECP, Fully Live
Session Type
Mental Health Policy
Date
Mon, 06.06.2022
Session Time
12:00 - 12:45
Room
Hall A
Session Icon
Fully Live
Session Type
Industry
Date
Mon, 06.06.2022
Session Time
13:00 - 13:45
Room
Industry session hall 2
Session Description
Treatment-resistant schizophrenia – What’s holding us back? -Supported by Viatris

Session Description:

Despite the existence of more than 60 antipsychotic therapeutic agents globally 20-30% of schizophrenia patients are resistant to treatment. There is a direct correlation between treatment initiation and improved clinical outcomes in treatment-resistant schizophrenia (TRS), thus defining treatment resistance in schizophrenia patients is utmost important, so that appropriate treatment can be administered as early as possible. Clozapine is the only evidence-based, effective, and approved treatment for TRS. Despite the evidence for its use, clozapine continues to be highly underutilized and initiated late. Failure to recognize TRS is an important clinical barrier to earlier initiation of clozapine. Clinicians should routinely, actively assess patients with schizophrenia for inadequate response to treatment. In his talk Professor Ofer Agid will review the clinical and biological aspects of treatment response and treatment resistance in first-episode schizophrenia, discuss an algorithm-based treatment approach and emphasize the importance of early positioning of clozapine to reduce the duration of active psychosis. Professor Swaran Singh in his lecture will talk about the barriers and list the various factors leading to clozapine’s underutilization and, in many cases, to its delayed initiation. He will also share practical advice and actions needed to overcome these barriers.

Session Icon
Fully Live
Session Type
Educational
Date
Mon, 06.06.2022
Session Time
15:00 - 16:30
Room
Hall B
Session Description
Mariana Pinto da Costa will present the preliminary findings of the barriers of professional development of early-career psychiatrists survey. Ozge Kilic will present the comparison between males and females in the Barriers of Professional Development early career psychiatrists survey. Dr. Helen Fisher will address the ‘ask me anything sessions’ that are regular and open to any staff/students at King’s College London. interesting concept of having an open door and promoting the development of colleagues early in their careers. Last but not least, it will be interesting to hear Prof Norman Sartorius talk about what one should not do in their career to thrive.
Session Icon
ECP, Fully Live
Session Type
Industry
Date
Mon, 06.06.2022
Session Time
19:00 - 20:30
Room
Industry session hall 2
Session Description
Pieces of the Cognitive Impairment Puzzle: Individual Domains in Schizophrenia-Supported by Boehringer Ingelheim

Session Description:

Cognitive impairment associated with schizophrenia (CIAS) is a central feature of the condition and is associated with deficits across multiple cognitive domains. CIAS is a significant predictor of real-world functioning, affecting one’s ability to live independently, be gainfully employed, and have meaningful interpersonal relationships. Existing pharmacological treatments for schizophrenia fall short in meeting the need associated with cognitive impairments, and non-pharmacological therapies, while recommended by current treatment guidelines, are limited in their ability to mitigate CIAS symptoms. This session will elucidate the current understanding of CIAS and its underlying physiology; explain the importance of dopaminergic and glutamatergic signaling, including the potential role of the N-methyl-D-aspartate (NMDA) receptor and glycine transporter type-1 (GlyT1) function in cognition; and highlight the impact of CIAS from the patient perspective. This compelling session will then discuss GlyT1 inhibition as a potential target for CIAS and present Phase II data on Boehringer Ingelheim’s investigational therapeutic GlyT1 inhibitor, BI 425809.

Session Icon
Fully Live
Session Type
Clinical/Therapeutic
Date
Tue, 07.06.2022
Session Time
08:00 - 09:30
Room
Hall C
Session Icon
Fully Live
Session Type
Clinical/Therapeutic
Date
Tue, 07.06.2022
Session Time
10:00 - 10:45
Room
Hall C
Session Icon
Fully Live

Tuesday, 7 June: Midday Interviews

Session Type
EPA TV
Date
Tue, 07.06.2022
Session Time
11:30 - 12:00
Room
EPA TV
Session Icon
Fully Live, Live TV

Tuesday, 7 June: EPA Focus

Session Type
EPA TV
Date
Tue, 07.06.2022
Session Time
14:30 - 15:00
Room
EPA TV
Session Icon
Fully Live, Live TV

Presenter Of 20 Presentations

Presentation of EPA Solidarity Network and its activities

Session Type
EPA Forum
Date
Sat, 04.06.2022
Session Time
09:00 - 12:00
Room
Hall A
Session Icon
Fully Live
Lecture Time
10:30 - 10:40

Council of NPAs

Session Type
Committee Meeting
Date
Sat, 04.06.2022
Session Time
14:00 - 17:00
Room
Meeting Room 1
Lecture Time
14:00 - 17:00

Award Ceremony

Session Type
Opening Ceremony
Date
Sat, 04.06.2022
Session Time
18:30 - 19:30
Room
Hall A
Session Icon
Fully Live
Lecture Time
18:50 - 19:05

Introduction

Session Type
Industry
Date
Mon, 06.06.2022
Session Time
13:00 - 13:45
Room
Industry session hall 2
Session Icon
Fully Live
Lecture Time
13:00 - 13:03

The Cognitive Impairment Puzzle

Session Type
Industry
Date
Mon, 06.06.2022
Session Time
19:00 - 20:30
Room
Industry session hall 2
Session Icon
Fully Live
Lecture Time
19:00 - 19:10

EPA Pascal Boyle Prize announcement

Session Type
Opening Ceremony
Date
Sat, 04.06.2022
Session Time
18:30 - 19:30
Room
Hall A
Session Icon
Fully Live
Lecture Time
19:05 - 19:10

Q&A

Session Type
Industry
Date
Mon, 06.06.2022
Session Time
13:00 - 13:45
Room
Industry session hall 2
Session Icon
Fully Live
Lecture Time
13:37 - 13:42

Putting the pieces together: GlyT1 as a potential treatment target for CIAS

Session Type
Industry
Date
Mon, 06.06.2022
Session Time
19:00 - 20:30
Room
Industry session hall 2
Session Icon
Fully Live
Lecture Time
20:00 - 20:25

Presidential Lecture

Session Type
Opening Ceremony
Date
Sat, 04.06.2022
Session Time
18:30 - 19:30
Room
Hall A
Session Icon
Fully Live
Lecture Time
19:10 - 19:20

Closing remarks

Session Type
Industry
Date
Mon, 06.06.2022
Session Time
13:00 - 13:45
Room
Industry session hall 2
Session Icon
Fully Live
Lecture Time
13:42 - 13:45

Executive Committee Meeting

Summary and Close

Session Type
Industry
Date
Mon, 06.06.2022
Session Time
19:00 - 20:30
Room
Industry session hall 2
Session Icon
Fully Live
Lecture Time
20:25 - 20:30

Welcome and Introduction

Session Type
EPA Forum
Date
Sat, 04.06.2022
Session Time
09:00 - 12:00
Room
Hall A
Session Icon
Fully Live
Lecture Time
09:00 - 09:05

Closing address

Session Type
Opening Ceremony
Date
Sat, 04.06.2022
Session Time
18:30 - 19:30
Room
Hall A
Session Icon
Fully Live
Lecture Time
19:20 - 19:30

Presentation on the needs in psychiatric research

Session Type
EPA Forum
Date
Sat, 04.06.2022
Session Time
09:00 - 12:00
Room
Hall A
Session Icon
Fully Live
Lecture Time
09:15 - 09:25

Welcome and Presidential Address

Session Type
Opening Ceremony
Date
Sat, 04.06.2022
Session Time
18:30 - 19:30
Room
Hall A
Session Icon
Fully Live
Lecture Time
18:30 - 18:35

Session 3: Roundtable Discussion on the Call for a European Year for Mental Health - moderated by Peter Falkai and Geert Dom

Covid-19: Lessons for Mental and Brain Health

Session Type
Clinical/Therapeutic
Date
Sun, 05.06.2022
Session Time
15:00 - 16:30
Room
Hall A
Session Icon
Fully Live
Lecture Time
15:51 - 15:59

Abstract

Abstract Body

Psychiatry is facing major challenges during times of a pandemic as illustrated by the current COVID-19 pandemic. The challenges involve its actual and perceived role within the medical system, in particular how psychiatric hospitals can maintain their core mission of attending to the mentally ill while at the same time providing relief to general medicine. Since psychiatric disorders are the top leading causes of global burden of disease, we need to strengthen mental health care in the wake of the massive onslaught of the pandemic. While nobody can deny the need to act decisively and swiftly and ramp up intensive care readiness, we believe that the immediate availability of psychiatric care is just as important. In order to provide the best possible treatment conditions for people suffering from mental illness but as well for those suffering from the immediate pandemic’s consequences such as isolation, reduced social interaction etc. instant and comprehensive provision is inevitable.

Hide

How to Improve the Physical Health in Patients with Severe Mental Disorders

Session Type
Clinical/Therapeutic
Date
Sat, 04.06.2022
Session Time
08:00 - 09:30
Room
On Demand 1
Session Icon
On Demand
Lecture Time
08:40 - 09:00

Abstract

Abstract Body

Schizophrenia is a severe brain disorder characterised by positive, negative, affective and cognitive symptoms and can be regarded as a disorder of impaired neural plasticity. This lecture focusses on the beneficial role of exercise in schizophrenia and its underlying mechanisms.Apart from the established pharmacological treatments in schizophrenia, aerobic exercise has a profound impact on the plasticity of the brain of both rodents and humans such as inducing the proliferation and differentiation of neural progenitor cells of the hippocampus in mice and rats. Aerobic exercise enhances LTP and leads to a better performance in hippocampus related memory tasks, eventually by increasing metabolic and synaptic plasticity related proteins in the hippocampus. In healthy humans, regular aerobic exercise increases hippocampal volume and seems to diminish processes of ageing like brain atrophy and cognitive decline.Several meta-analyses demonstrate the beneficial effect of exercise on function, positive as well as negative symptoms and brain structure in multi-episode schizophrenia.

Hide